Trough tacrolimus concentrations in the first week after kidney transplantation are related to acute rejection

Therapeutic Drug Monitoring

Volumn 31, Issue 4, 2009, Pages 436-442

  Borobia, Alberto M ^a   Romero, Ivan ^a   Jimenez, Carlos ^b   Gil, Fernando ^b   Ramirez, Elena ^a   Gracia, Raquel De ^b   Escuin, Fernando ^b   Gonzalez, Elena ^b   Sansuán, Antonio J Carcas ^a,b  

^a Institute of Neurosciences   (Spain)

^b AUTONOMOUS UNIVERSITY OF MADRID   (Spain)

Author keywords

Kidney transplantation; Tacrolimus; Words: acute rejection

Indexed keywords

BASILIXIMAB; CREATININE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; RAPAMYCIN; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; AGE DISTRIBUTION; ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG TREATMENT FAILURE; FEMALE; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY ALLOGRAFT REJECTION; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE; SURGICAL PATIENT; SURVIVAL TIME;

GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; TACROLIMUS;

EID: 68449089526     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3181a8f02a     Document Type: Article

References (33)

1. Knoll GA, Bell RC. Tacrolimus versus cyclosporin for immunosuppression in renal transplantation: meta-analysis of randomised trials. BMJ. 1999;318:1104-1107.
2. Pirsch JD, Miller J, Deierhoi MH, et al. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation. 1997;63:977-983.
3. Webster AC, Woodroffe RC, Taylor RS, et al. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. BMJ. 2005;331:810.
4. Shapiro R. Tacrolimus (FK-506) in kidney transplantation. Transplant Proc. 1997;29:45-47.
5. Ciancio G, Burke GW, Gaynor JJ, et al. A randomized long-term trial of tacrolimus/sirolimus versus tacrolimums/mycophenolate versus cyclosporine. Transplantation. 2006;81:845-852.
6. Kramer BK, Montagnino G, Del Castillo D, et al. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results. Nephrol Dial Transplant. 2005;20:968-973.
7. Margreiter R. Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: a randomised multicentre study. Lancet. 2002;359:741-746.
8. Mayer AD, Dmitrewski J, Squifflet JP, et al. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group. Transplantation. 1997;64:436-443.
9. Samaniego M, Bryan N, Becker BN, et al. Drug insight: maintenance immunosuppression in kidney transplant recipients. Nat Clin Pract Nephrol. 2006;2:688-699.
10. Meier-Kriesche HU, Schold JD, Srinivas TR, et al. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant. 2004;4:378-383.
11. Ihara H, Shinkuma D, Ichikawa Y, et al. Intra- and interindividual variation in the pharmacokinetics of tacrolimus (FK506) in kidney transplant recipients-importance of trough level as a practical indicator. Int J Urol. 1995;2:151-155.
12. Jusko WJ. Analysis of tacrolimus (FK 506) in relation to therapeutic drug monitoring. Ther Drug Monit. 1995;17:596-601.
13. Staatz C, Taylor P, Tett S. Low tacrolimus concentrations and increased risk of early acute rejection in adult renal transplantation. Nephrol Dial Transplant. 2001;16:1905-1909.
14. Venkataramanan R, Swaminathan A, Prasad T, et al. Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet. 1995;29:404-430.
15. Wong W, Venetz JP, Tolkoff-Rubin N, et al. 2005 immunosuppressive strategies in kidney transplantation: which role for the calcineurin inhibitors? Transplantation. 2005;80:289-296.
16. Kaplan B, Titte R, Srinivas TR, et al. Factors associated with long-term renal allograft survival. Ther Drug Monit. 2002;24:36-39.
17. Pascual M, Theruvath T, Kawai T, et al. Strategies to improve long-term outcomes after renal transplantation. N Engl J Med. 2002;346:580-590.
18. Mahalati K, Belitsky P, Sketris I, et al. Neoral monitoring by simplified sparse sampling area under the concentration-time curve: its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation. Transplantation. 1999;68:55-62.
19. Matas AJ, Gillingham KJ, Chavers BM, et al. The importance of early cyclosporine levels in pediatric kidney Transplantation. Clin Transplant. 1996;10:482-486.
20. Undre NA, van Hooff J, Christiaans M, et al. Low systemic exposure to tacrolimus correlates with acute rejection. Transplant Proc. 1999;31:296-298.
21. Kuypers DR, Claes K, Evenepoel P, et al. Clinical efficacy and toxicity profile of tacrolimus and mycophenolic acid in relation to combined longterm pharmacokinetics in de novo renal allograft recipients. Clin Pharmacol Ther. 2004;75:434-447.
22. Laskow DA, Vincenti F, Neylan JF, et al. An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: a report of the United States Multicenter FK506 Kidney Transplant Group. Transplantation. 1996;62:900-905.
23. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982;143:29-36.
24. Bautista D, Arana E, Martí-Bonmatí L, et al. Validation of logistic regression models in small samples: application to calvarial lesions diagnosis. J Clin Epidemiol. 1999;52:237-241.
25. Denton MD, Magee CC, Sayegh MH. Immunosuppressive strategies in Transplantation. Lancet. 1999;353:1083-1091.
26. Game DS, Lechler RI. Pathways of allorecognition: implications for transplantation tolerance. Transpl Immunol. 2002;10:101-108.
27. de Fijter JW. The impact of age on rejection in kidney Transplantation. Drugs Aging. 2005;22:433-449.
28. Cosio FG, Amer H, Joseph P, et al. Comparison of low versus high tacrolimus levels in kidney transplantation: assessment of efficacy by protocol biopsies. Transplantation. 2007;83:411-416.
29. Gaber LW, Moore LW, Reed L, et al. Renal histology with varying FK506 blood levels. Transplant Proc. 1997;29:186.
30. Kershner RP, Fitzsimmons WE. Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney Transplantation. Transplantation. 1996;62:920-926.
31. Le Meur Y, Buchler M, Thierry A, et al. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal Transplantation. Am J Transplant. 2007;7:2496-2503.
32. West-Thielke P, Kaplan B. Therapeutic monitoring of mycophenolic acid: is there clinical utility? Am J Transplant. 2007;7:2441-2442.
33. Squifflet JP, Backman L, Claesson K, et al. Dose optimization of mycophenolate mofetil when administered with a low dose of tacrolimus in cadaveric renal transplant recipients. Transplantation. 2001;72:63-69.